BRAF gene has been identified as an oncogenic driver and a potential target in various
malignancies. BRAF fusions are one subtype of BRAF alterations with a rare frequency …

Background Histone deacetylases (HDAC) contribute to oncogenic program, pointing to
their inhibitors as a potential strategy against cancers. We, thus, studied the mechanism of …

Objective In this review, we aim to summarize the most recent data on the surgical
management of oligometastatic non-small cell lung cancer (NSCLC). Background …

Introduction The adjuvant treatment of patients with resected lung adenocarcinoma (LUAD)
remains unstandardized. We analyzed the survival outcomes of these patients based on …

Introduction The frequency of actionable mutations varies between races, and
Hispanic/Latino (H/L) people are a population with different proportions of ancestry. Our …

Introduction Cancer immunotherapy represents one of the most important innovations in
modern medicine. Durvalumab is an anti-programmed cell death ligand 1 (PDL-1) agent …

Background: Nivolumab has been approved in China as second-line treatment for advanced
non-small-cell lung cancer (NSCLC) via weight-based infusion, based on the CheckMate …

Objective. Since the inefficient cancer management is caused by inaccurate diagnoses,
there is a need for minimally invasive method to improve the diagnostic accuracy of non …

Background Despite the progress in the development of next‐generation sequencing (NGS),
diagnostic PCR assays remain to be utilized in clinical routine due to their simplicity and low …

In recent years, there has been an expansion in the treatment options of non-small cell lung
cancer (NSCLC) with the advent of targeted therapies and immuno-oncology therapies [1 …